MedTrace Logo

Cannabinoids for Pain Control During Medical Abortion

NCT03604341 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2020-04-07

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine if a synthetic cannabis derivative, dronabinol, in addition to ibuprofen, decreases maximum pain scores compared to ibuprofen and placebo in women undergoing medical abortion. Results of this study will help providers counsel patients regarding cannabis use during medical abortion.

Conditions

  • Medical Abortion
  • Pain

Interventions

DRUG

Dronabinol 5mg Cap

Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain

OTHER

Placebo

Subjects randomized to placebo and ibuprofen 800mg for pain

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
89 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2019-05-07
Completion
2019-05-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03604341 on ClinicalTrials.gov